NCT00454805 2016-08-03AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.AstraZenecaPhase 2 Completed75 enrolled 11 charts
NCT00475956 2010-04-15Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid TumoursAstraZenecaPhase 1 Completed40 enrolled